drugset / Trial / NCT05973734

Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy

NCT05973734 ↗

Phase 1 Enrolling by invitation 24 enrolled Stanford University University of California, San Francisco · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to learn if patients who have brittle type 1 diabetes receiving an islet transplantation will have better control of their sugars if they also receive one of 2 types of immune cells along with the islet transplant. The participants will receive either their own immune cells, called regulatory T cells, or immune cells from the bone marrow of the islet donor.

Timeline

Start
2024-04-15
Primary completion
2030-12
Completion
2030-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Infusion of concomitant Donor Derived Vertebral Bone Marrow Cell therapy — Other
Subject Infusion of recipient T regulatory cell Cell therapy — Other

Indications

No indication recorded.